Clinical features and treatment outcomes of PD-1 inhibitor therapy in elderly patients ( ≥ 65 years) with advanced esophageal squamous cell carcinoma: a real-world study

ConclusionThe study demonstrated that individuals older than 65  years with locally advanced or metastatic ESCC have a survival benefit from the first-line treatment of PD-1 inhibitors combined therapy, with a manageable safety profile.
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research